PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2.
作者信息
McDonagh Ellen M, Boukouvala Sotiria, Aklillu Eleni, Hein David W, Altman Russ B, Klein Teri E
机构信息
Departments of aGenetics bBioengineering, Stanford University, Palo Alto, California cDepartment of Pharmacology and Toxicology and James Graham Brown Cancer Center, University of Louisville, Kentucky, USA dDepartment of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, Greece eDepartment of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Stockholm, Sweden.
出版信息
Pharmacogenet Genomics. 2014 Aug;24(8):409-25. doi: 10.1097/FPC.0000000000000062.
Abstract
摘要
相似文献
1
PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2.药物基因组知识库总结：N-乙酰转移酶2的非常重要的药物基因信息。
Pharmacogenet Genomics. 2014 Aug;24(8):409-25. doi: 10.1097/FPC.0000000000000062.
2
Phenotyping with sulfasalazine - time dependence and relation to NAT2 pharmacogenetics.柳氮磺胺吡啶表型分析——时间依赖性及其与NAT2药物遗传学的关系
Int J Clin Pharmacol Ther. 2010 Jan;48(1):1-10. doi: 10.5414/cpp48001.
3
Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1).人类芳胺N-乙酰基转移酶1（NAT1）的基因型与表型之间的相关性
Biochem Pharmacol. 1999 Dec 1;58(11):1759-64. doi: 10.1016/s0006-2952(99)00269-5.
4
[Pharmacogenetics of disease modifying anti-rheumatic drugs].[改善病情抗风湿药物的药物遗传学]
Nihon Rinsho. 2002 Dec;60(12):2339-44.
5
Genetic polymorphism of conjugating enzymes and cancer risk: GSTM1, GSTT1, NAT1 and NAT2.结合酶的基因多态性与癌症风险：谷胱甘肽 S-转移酶 M1、谷胱甘肽 S-转移酶 T1、N-乙酰基转移酶 1 和 N-乙酰基转移酶 2
J Toxicol Sci. 1998 Jul;23 Suppl 2:140-2.
6
Arylamine N-acetyltransferase in erythrocytes of cystic fibrosis patients.囊性纤维化患者红细胞中的芳胺N-乙酰基转移酶
Pharmacol Toxicol. 1996 Apr;78(4):235-40. doi: 10.1111/j.1600-0773.1996.tb00211.x.
7
8
Sequences and expression of alleles of polymorphic arylamine N-acetyltransferase of human liver.人类肝脏中多态性芳胺N-乙酰基转移酶等位基因的序列与表达
J Biol Chem. 1992 Sep 5;267(25):18140-7.
9
The pharmacogenetics of NAT: structural aspects.N-乙酰基转移酶的药物遗传学：结构方面
Pharmacogenomics. 2002 Jan;3(1):19-30. doi: 10.1517/14622416.3.1.19.
10
Arylamine N-acetyltransferase 2 gene polymorphism in an Algerian population.阿尔及利亚人群中芳胺N-乙酰基转移酶2基因多态性
Ann Hum Biol. 2017 Sep;44(6):531-536. doi: 10.1080/03014460.2017.1311373. Epub 2017 Apr 18.
引用本文的文献
1
Residue Variations in Human N‑Acetyltransferase 2 Enzyme Alleles: From Rapid to Slow Acetylation.人类N-乙酰基转移酶2酶等位基因中的残基变异：从快速乙酰化到缓慢乙酰化。
ACS Omega. 2025 Jul 27;10(30):33045-33062. doi: 10.1021/acsomega.5c02316. eCollection 2025 Aug 5.
2
Pharmacokinetics of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum with and without efavirenz-based antiretroviral treatment: IMPAACT P1026s study.一线抗结核药物利福平、异烟肼、乙胺丁醇和吡嗪酰胺在孕期及产后使用和不使用基于依非韦伦的抗逆转录病毒治疗时的药代动力学：IMPAACT P1026s研究
Antimicrob Agents Chemother. 2025 Sep 3;69(9):e0005225. doi: 10.1128/aac.00052-25. Epub 2025 Jul 31.
3
Population pharmacokinetics of pyrazinamide and isoniazid in plasma and cerebrospinal fluid from South African adults with tuberculous meningitis.南非结核性脑膜炎成年患者血浆和脑脊液中吡嗪酰胺及异烟肼的群体药代动力学
Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0009925. doi: 10.1128/aac.00099-25. Epub 2025 Jul 1.
4
Anti-tuberculosis drug-induced hepatotoxicity and associated risk factors among patients with pulmonary tuberculosis at a tertiary care hospital in Thailand.泰国一家三级护理医院肺结核患者中抗结核药物引起的肝毒性及相关危险因素
IJID Reg. 2025 May 8;15:100665. doi: 10.1016/j.ijregi.2025.100665. eCollection 2025 Jun.
5
Unveiling the heritability of selected unexplored pharmacogenetic markers in the Saudi population.揭示沙特人群中选定的未探索药物遗传标记的遗传力。
Front Pharmacol. 2025 May 1;16:1559399. doi: 10.3389/fphar.2025.1559399. eCollection 2025.
6
NAT2 Acetylation Status Predicts Hepatotoxicity During Antituberculosis Therapy: Cumulative Risk Analysis of a Multiethnic Cohort.NAT2乙酰化状态可预测抗结核治疗期间的肝毒性：多民族队列的累积风险分析
Int J Mol Sci. 2025 Apr 19;26(8):3881. doi: 10.3390/ijms26083881.
7
Metabolism and genotoxicity of 4,4'-oxydianiline is dependent on N-acetyltransferase 2 genetic polymorphism.4,4'-氧化二苯胺的代谢和遗传毒性取决于N-乙酰转移酶2基因多态性。
Environ Toxicol Pharmacol. 2025 Jun;116:104699. doi: 10.1016/j.etap.2025.104699. Epub 2025 Apr 15.
8
Pharmacogenomic heterogeneity of : a comprehensive analysis of real world data in Indian tuberculosis patients and from literature and database review.的药物基因组学异质性：对印度结核病患者真实世界数据以及文献和数据库回顾的综合分析。 （注：原英文表述不太完整规范，可能影响理解其确切所指，但按要求逐字翻译如此）
Ann Med. 2025 Dec;57(1):2478316. doi: 10.1080/07853890.2025.2478316. Epub 2025 Mar 26.
9
Characterization of NAT, GST, and CYP2E1 Genetic Variation in Sub-Saharan African Populations: Implications for Treatment of Tuberculosis and Other Diseases.撒哈拉以南非洲人群中NAT、GST和CYP2E1基因变异的特征：对结核病和其他疾病治疗的影响。
Clin Pharmacol Ther. 2025 May;117(5):1338-1357. doi: 10.1002/cpt.3557. Epub 2025 Jan 20.
10
Pharmacogenomic landscape of the Thai population from genome sequencing of 949 individuals.通过对949名个体进行基因组测序解析泰国人群的药物基因组学概况。
Sci Rep. 2024 Dec 28;14(1):30683. doi: 10.1038/s41598-024-79018-6.
本文引用的文献
1
N-acetyltransferase 2 polymorphisms and risk of esophageal cancer in a Chinese population.中国人群中N-乙酰转移酶2基因多态性与食管癌风险
PLoS One. 2014 Feb 19;9(2):e87783. doi: 10.1371/journal.pone.0087783. eCollection 2014.
2
Pharmacokinetics of isoniazid in low-birth-weight and premature infants.低体重和早产儿中异烟肼的药代动力学
Antimicrob Agents Chemother. 2014;58(4):2229-34. doi: 10.1128/AAC.01532-13. Epub 2014 Feb 3.
3
Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery.芳香胺 N-乙酰基转移酶：从药物代谢和药物遗传学到药物发现。
Br J Pharmacol. 2014 Jun;171(11):2705-25. doi: 10.1111/bph.12598.
4
Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension.NAT2基因的不同表型影响顽固性高血压患者的肼屈嗪降压反应。
Pharmacogenomics. 2014 Feb;15(2):169-78. doi: 10.2217/pgs.13.202.
5
Correlation of N-acetyltransferase 2 genotype with isoniazid acetylation in Polish tuberculosis patients.波兰结核病患者中N-乙酰转移酶2基因型与异烟肼乙酰化的相关性
Biomed Res Int. 2013;2013:853602. doi: 10.1155/2013/853602. Epub 2013 Dec 7.
6
N-acetyltransferase 2 genetic variants confer the susceptibility to head and neck carcinoma: evidence from 23 case-control studies.N-乙酰基转移酶2基因变异赋予头颈部癌易感性：来自23项病例对照研究的证据。
Tumour Biol. 2014 Apr;35(4):3585-95. doi: 10.1007/s13277-013-1473-9. Epub 2013 Dec 13.
7
CYP2E1 and NQO1 genotypes and bladder cancer risk in a Lebanese population.黎巴嫩人群中CYP2E1和NQO1基因分型与膀胱癌风险
Int J Mol Epidemiol Genet. 2013 Nov 28;4(4):207-17. eCollection 2013.
8
Determination of urine caffeine and its metabolites by use of high-performance liquid chromatography-tandem mass spectrometry: estimating dietary caffeine exposure and metabolic phenotyping in population studies.采用高效液相色谱-串联质谱法测定尿中咖啡因及其代谢物：在人群研究中估算饮食中咖啡因的暴露量和代谢表型。
Anal Bioanal Chem. 2014 Jan;406(3):771-84. doi: 10.1007/s00216-013-7506-9. Epub 2013 Dec 4.
9
Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk.对乙酰基转移酶 2（NAT2）表型与酶活性和膀胱癌风险的预测进行优化。
Arch Toxicol. 2013 Dec;87(12):2129-39. doi: 10.1007/s00204-013-1157-7. Epub 2013 Nov 13.
10
Genome-wide association study identifies multiple loci associated with bladder cancer risk.全基因组关联研究确定了多个与膀胱癌风险相关的基因座。
Hum Mol Genet. 2014 Mar 1;23(5):1387-98. doi: 10.1093/hmg/ddt519. Epub 2013 Oct 24.
Zotero 插件